Case 2: 82-Year-Old Former Smoker with Poorly Differentiated Lung Adenocarcinoma and PD-L1 of 85%

February 20, 2024

By Gregory Gan, MD, PhD
Alykhan Nagji, MD

Opinion

Video

Dr. Gregory Gan introduces Case 2, featuring an 82-year-old former smoker with poorly differentiated lung adenocarcinoma and a PD-L1 level of 85%, initiating a conversation on the role of a multidisciplinary approach to treatment and consideration factors for surgical and radiotherapy interventions.

EP: 1.Available Treatment Options for Patients With Stage-III Resectable NSCLC

EP: 2.Determining Eligibility for Surgical Resection in NSCLC

EP: 3.Expert Perspectives on Perioperative Immunotherapy in Resectable Stage-III NSCLC

EP: 4.Treatment Approaches for Resectable Stage-III NSCLC in the Adjuvant Setting

EP: 5.Treatment Strategies for NSCLC Following Progression on Adjuvant Immunotherapy

EP: 6.Approaches to Treatment and Staging in Unresectable NSCLC

EP: 7.Sequential and Concurrent Chemoradiotherapy in Unresectable Stage-III NSCLC

EP: 8.Expert Insights on Adjuvant Immunotherapy in Unresectable Stage-III NSCLC

EP: 9.Managing Stage-III NSCLC with Actionable EGFR or ALK Mutations

EP: 10.The Potential Role of Combination Adjuvant Immunotherapy in NSCLC

EP: 11.Insights into Strategies Using Concurrent Immunotherapy with Chemoradiotherapy

EP: 12.Clinical Pearls for Treating NSCLC: Insights from Experts at the University of Kansas

EP: 13.Case 1: 72-Year-Old Former Smoker with Stage-IIIA NSCLC and PD-L1 of 90%

Now Viewing

EP: 14.Case 2: 82-Year-Old Former Smoker with Poorly Differentiated Lung Adenocarcinoma and PD-L1 of 85%

EP: 15.Case 3: 70-Year-Old Former Smoker with Stage IIIB NSCLC with PD-L1 10%

EP: 16.Case 4: 71-Year-Old Diagnosed with Stage IIIA NSCLC Experiencing Pneumonitis After Chemo-IO Treatment

EP: 17.A Multidisciplinary Approach to Treating Resectable NSCLC

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!